Miklos Z Molnar1, Vanessa Ravel2, Elani Streja2, Csaba P Kovesdy3,4, Matthew B Rivara5, Rajnish Mehrotra5, Kamyar Kalantar-Zadeh2. 1. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. mzmolnar@uthsc.edu. 2. Division of Nephrology, University of California, Irvine, California. 3. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 4. Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee. 5. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington.
Abstract
OBJECTIVES: To compare the mortality of elderly adults with end-stage renal disease (ESRD) treated with home hemodialysis (HD) with that of those receiving a kidney transplant (KTx). DESIGN: Prospective cohort. SETTING: Pertinent data for the two groups were obtained from electronic medical records from a large dialysis provider and the U.S. Renal Data System. PARTICIPANTS: Using data from elderly adults (aged ≥65) who started home HD and underwent KTx in the US between 2007 and 2011, a 1:1 propensity score (PS)-matched cohort of 960 elderly adults was created, and the association between treatment modality and all-cause mortality was examined using Cox proportional hazards and competing risk regression survival models using modality failure as a competing event. MEASUREMENTS: Modality of renal replacement therapy. RESULTS: The baseline mean age ± standard deviation of the PS-matched individuals undergoing home HD was 71 ± 6, and that of KTx recipients was 71 ± 5, 69% of both groups were male, 81% of those undergoing home HD and 79% of KTx recipients were white, and 11% and 12%, respectively, were African American. Median follow-up time was 205 days (interquartile range (IQR) 78-364 days) for those undergoing home HD and 795 days (IQR 366-1,221 days) for KTx recipients. There were 97 deaths (20%, 253/1,000 patient-years, 95% confidence interval (CI) = 207-309/1,000 patient-years) in the home HD group and 48 deaths (10%, 45/1,000 patient-years, 95% CI = 34-60/1,000 patient-years) in the KTx group. Elderly adults undergoing home HD had a risk of mortality that was almost five times as high as that of KTx recipients (hazard ratio = 4.74, 95% CI = 3.25-6.91). Similar results were seen in competing risk regression analyses (subhazard ratio = 4.71, 95% CI = 3.27-6.79). Results were consistent across different types of kidney donors and subgroups divided according to various recipient characteristics. CONCLUSION: Elderly adults with ESRD who receive a KTx have greater survival than those who undergo home HD. Further studies are needed to assess whether KTx receipt is associated with other benefits such as better quality of life and lower hospitalization rates.
OBJECTIVES: To compare the mortality of elderly adults with end-stage renal disease (ESRD) treated with home hemodialysis (HD) with that of those receiving a kidney transplant (KTx). DESIGN: Prospective cohort. SETTING: Pertinent data for the two groups were obtained from electronic medical records from a large dialysis provider and the U.S. Renal Data System. PARTICIPANTS: Using data from elderly adults (aged ≥65) who started home HD and underwent KTx in the US between 2007 and 2011, a 1:1 propensity score (PS)-matched cohort of 960 elderly adults was created, and the association between treatment modality and all-cause mortality was examined using Cox proportional hazards and competing risk regression survival models using modality failure as a competing event. MEASUREMENTS: Modality of renal replacement therapy. RESULTS: The baseline mean age ± standard deviation of the PS-matched individuals undergoing home HD was 71 ± 6, and that of KTx recipients was 71 ± 5, 69% of both groups were male, 81% of those undergoing home HD and 79% of KTx recipients were white, and 11% and 12%, respectively, were African American. Median follow-up time was 205 days (interquartile range (IQR) 78-364 days) for those undergoing home HD and 795 days (IQR 366-1,221 days) for KTx recipients. There were 97 deaths (20%, 253/1,000 patient-years, 95% confidence interval (CI) = 207-309/1,000 patient-years) in the home HD group and 48 deaths (10%, 45/1,000 patient-years, 95% CI = 34-60/1,000 patient-years) in the KTx group. Elderly adults undergoing home HD had a risk of mortality that was almost five times as high as that of KTx recipients (hazard ratio = 4.74, 95% CI = 3.25-6.91). Similar results were seen in competing risk regression analyses (subhazard ratio = 4.71, 95% CI = 3.27-6.79). Results were consistent across different types of kidney donors and subgroups divided according to various recipient characteristics. CONCLUSION: Elderly adults with ESRD who receive a KTx have greater survival than those who undergo home HD. Further studies are needed to assess whether KTx receipt is associated with other benefits such as better quality of life and lower hospitalization rates.
Authors: Eric D Weinhandl; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: H Myron Kauffman; Maureen A McBride; Cynthia S Cors; Allan M Roza; James J Wynn Journal: Transplantation Date: 2007-02-27 Impact factor: 4.939
Authors: Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns Journal: JAMA Date: 2007-09-19 Impact factor: 56.272
Authors: Michael Walsh; Braden J Manns; Scott Klarenbach; Marcello Tonelli; Brenda Hemmelgarn; Bruce Culleton Journal: Hemodial Int Date: 2009-12-22 Impact factor: 1.812
Authors: Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Elani Streja; Connie M Rhee; Melissa Soohoo; Joline L T Chen; Miklos Z Molnar; Yoshitsugu Obi; Daniel Gillen; Danh V Nguyen; Keith C Norris; John J Sim; Steve S Jacobsen Journal: Nephrol Dial Transplant Date: 2017-04-01 Impact factor: 5.992
Authors: Jerry Z Yu; Connie M Rhee; Antoney Ferrey; Alex Li; Anna Jin; Yongen Chang; Uttam Reddy; Wei Ling Lau; Jason Chou; Jula Inrig; Kamyar Kalantar-Zadeh Journal: Semin Dial Date: 2017-12-18 Impact factor: 3.455
Authors: Percy Herrera-Añazco; Pedro J Ortiz; Jesus E Peinado; Tania Tello; Fabiola Valero; Adrian V Hernandez; J Jaime Miranda Journal: Int Health Date: 2020-02-12 Impact factor: 2.473
Authors: Tessa S Schoot; Namiko A Goto; Rob J van Marum; Luuk B Hilbrands; Angèle P M Kerckhoffs Journal: Int Urol Nephrol Date: 2022-05-06 Impact factor: 2.266
Authors: Angie G Nishio-Lucar; Subhasish Bose; Genevieve Lyons; Kwabena T Awuah; Jennie Z Ma; Robert S Lockridge Journal: Kidney Int Rep Date: 2020-01-09